Evidence map›Paper›PMID 35917738›Full record

ArticleParkinsonism & related disorders2022

Polygenic risk prediction and SNCA haplotype analysis in a Latino Parkinson's disease cohort.

Douglas P Loesch, Andrea R V R Horimoto, Elif Irem Sarihan, Miguel Inca-Martinez, Emily Mason, Mario Cornejo-Olivas, Luis Torres, Pilar Mazzetti, Carlos Cosentino, Elison Sarapura-Castro and 27 more

Open access · hybridAbstract read
In one paragraph

Article in Parkinsonism & related disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 16 institutions in 6 countries.

Douglas P LoeschInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA; Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Andrea R V R HorimotoDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Elif Irem SarihanLerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, OH, USA.
Miguel Inca-MartinezLerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, OH, USA.
Emily MasonLerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, OH, USA.
Mario Cornejo-OlivasNeurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru; Center for Global Health, Universidad Peruana Cayetano Heredia, Lima, Peru.
Luis TorresMovement Disorders Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru; School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru.
Pilar MazzettiNeurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru; School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru.
Carlos CosentinoMovement Disorders Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru; School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru.
Elison Sarapura-CastroNeurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru.
Andrea Rivera-ValdiviaNeurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru.
Angel C MedinaUniversidad Nacional del Altiplano, Puno, Peru.
Elena DieguezNeurology Institute, Universidad de la República, Montevideo, Uruguay.
Victor RaggioDepartment of Genetics, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Andres LescanoDepartment of Genetics, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay.
Vitor TumasRibeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil.
Vanderci BorgesMovement Disorders Unit, Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil.
Henrique B FerrazMovement Disorders Unit, Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil.
Carlos R RiederDepartamento de Neurologia, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
Artur Schumacher-SchuhServiço de Neurologia, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Departamento de Farmacologia, Universidade Federal do Rio Grande do Sul, Brazil.
Bruno L Santos-LobatoInstituto de Ciências da Saúde, Universidade Federal do Pará, Belém, Brazil.
Carlos Velez-PardoNeuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Antioquia, Colombia.
Marlene Jimenez-Del-RioNeuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Antioquia, Colombia.
Francisco LoperaNeuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Antioquia, Colombia.
Sonia MorenoNeuroscience Research Group, Medical Research Institute, Faculty of Medicine, Universidad de Antioquia (UdeA), Medellín, Antioquia, Colombia.
Pedro Chana-CuevasCETRAM, Facultad de ciencias Medicas, Universidad de Santiago de Chile, Chile.
William FernandezNeuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia.
Gonzalo ArboledaNeuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia.
Humberto ArboledaNeuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia.
Carlos E Arboleda-BustosNeuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogotá, Colombia.
Dora YearoutVeterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Department of Neurology, University of Washington, Seattle, WA, USA.
Cyrus P ZabetianVeterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Department of Neurology, University of Washington, Seattle, WA, USA.
International Parkinson Disease Genomics Consortium (IPDGC)
Timothy A ThorntonDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Ignacio F MataLerner Research Institute, Genomic Medicine, Cleveland Clinic, Cleveland, OH, USA; Veterans Affairs Puget Sound Health Care System, Seattle, WA, USA; Department of Neurology, University of Washington, Seattle, WA, USA. Electronic address: matai@ccf.org.
Timothy D O'ConnorInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA; Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: timothydoconnor@gmail.com.
Latin American Research Consortium on the Genetics of Parkinson's Disease (LARGE-PD)
University of Washington · USUniversidad de Antioquia · COUniversidad Nacional de Colombia · COCleveland Clinic Lerner College of Medicine · USNational University of San Marcos · PEUniversidad de la República de Uruguay · UYInstituto Nacional de Ciencias NeurológicasUniversidade Federal de São Paulo · BRUniversity of Maryland, Baltimore · USUniversidad de Santiago de Chile · CLUniversidade de Ribeirão Preto · BRUniversidade Federal de Ciências da Saúde de Porto Alegre · BRUniversidade Federal do Pará · BRUniversidade Federal do Rio Grande do Sul · BRUniversidad Nacional del Altiplano · PEUniversidad Peruana Cayetano Heredia · PE

Funding

NPGH LEADERs YR12: OBSSR (Greenberg, Ngwafong Mukere) & NIBIB (Lee)D43TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI Dibyadyuti Datta, Chandy C. John · 2017 to 2026
$15.2M
Vascular Biology Training ProgramT32HL007698 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI Rosemary A Kozar, Dudley K. Strickland · 1991 to 2026
$8.7M
Modeling the impact of Women's Specific Health Factors in PD outcomes in LatinasR01NS112499 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI FERNANDEZ MATA, IGNACIO · 2020 to 2024
$3.3M
Rapid Evolution of Genomic Architecture and Multi-omics TraitsR35HG010692 · NHGRI · UNIVERSITY OF MARYLAND BALTIMORE · PI O'CONNOR, TIMOTHY DAVID · 2019 to 2023
$2.3M
FIC NIH HHS D43 TW009345NHGRI NIH HHS R35 HG010692NHLBI NIH HHS T32 HL007698NINDS NIH HHS R01 NS112499
6 · The paper itself

Abstract

backgroundLarge-scale Parkinson's disease (PD) genome-wide association studies (GWAS) have, until recently, only been conducted on subjects with European-ancestry. Consequently, polygenic risk scores (PRS) constructed using PD GWAS data are likely to be less predictive when applied to non-European cohorts.

methodsUsing GWAS data from the largest study to date, we constructed a PD PRS for a Latino PD cohort (1497 subjects from LARGE-PD) and tested it for association with PD status and age at onset. We validated the PRS performance by testing it in an independent Latino cohort (448 subjects) and by repeating the analysis in LARGE-PD with the addition of 440 external Peruvian controls. We also tested SNCA haplotypes for association with PD risk in LARGE-PD and a European-ancestry PD cohort.

resultsThe GWAS-significant PD PRS had an area under the receiver-operator curve (AUC) of 0.668 (95% CI: 0.640-0.695) in LARGE-PD. The inclusion of external Peruvian controls mitigated this result, dropping the AUC 0.632 (95% CI: 0.607-0.657). At the SNCA locus, haplotypes differ by ancestry. Ancestry-specific SNCA haplotypes were associated with PD status in both LARGE-PD and the European-ancestry cohort (p-value < 0.05). These haplotypes both include the rs356182 G-allele, but only share 14% of their variants overall.

conclusionThe PD PRS has potential for PD risk prediction in Latinos, but variability caused by admixture patterns and bias in a European-ancestry PD PRS data limits its utility. The inclusion of diverse subjects can help elucidate PD risk loci and improve risk prediction in non-European cohorts.

Indexed as

Genome-Wide Association StudyParkinson Diseasealpha-SynucleinGenetic Predisposition to DiseaseHaplotypesHispanic or LatinoHumansPolymorphism, Single NucleotideRisk Factorsalpha-SynucleinSNCA protein, human

Identifiers

PMID35917738
PMCPMC10112543
OpenAlexW4283071197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.